Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
University of Maryland reports research in cancer vaccines
March 26th, 2008
"Activation of tumor-reactive T lymphocytes is a promising approach for the prevention and treatment of patients with metastatic cancers. Strategies that activate CD8(+) T cells are particularly promising because of the cytotoxicity and specificity of CD8(+) T cells for tumor cells," scientists writing in the journal Cancer Immunology Immunotherapy report. "Optimal CD8(+) T cell activity requires the co-activation of CD4(+) T cells, which are critical for immune memory and protection against latent metastatic disease. Therefore, we are developing ''MHC II'' vaccines that activate tumor-reactive CD4(+) T cells. MHC II vaccines are MHC class I+ tumor cells that are...
Source: Vaccine Weekly (2008-03-26)
|
